Ozempic-maker sues rival, accusing it of false advertising
Novo Nordisk, the maker of Wegovy and Ozempic, has launched legal action accusing its arch rival Eli Lilly of false advertising.
Novo Nordisk, the Danish pharmaceutical company behind weight-loss and diabetes drugs Wegovy and Ozempic, has launched legal action against its US rival Eli Lilly, accusing it of false advertising.
According to the report from BBC Business, the dispute centres on claims made in the fast-growing market for medicines used to treat obesity. Novo Nordisk is challenging the way Eli Lilly has promoted its competing products, although the feed summary does not provide further detail on the specific statements at issue or where the case was filed.
The move adds a new legal dimension to the rivalry between two of the world’s biggest drugmakers, both of which have become central to the commercial boom in obesity treatments. Wegovy and Ozempic have helped make Novo Nordisk one of the most closely watched companies in global healthcare, while Eli Lilly has also expanded rapidly in the same market with its own competing medicines.
False advertising claims are often used when one company believes a competitor’s marketing overstated a product’s performance, benefits or comparison with rival treatments. In this case, however, the available feed information is limited, and the specific allegations made by Novo Nordisk have not been detailed.
The legal action comes at a time when demand for weight-loss medicines remains high and competition between manufacturers is intense. Both companies have been racing to meet surging interest from patients and healthcare providers, while also facing scrutiny over pricing, access and promotion.
The BBC Business report indicates only that Novo Nordisk has initiated proceedings against Eli Lilly. No response from Eli Lilly was included in the feed summary, and no further court or regulatory details were provided.
This article is based on a monitored public feed and has been prepared from the available summary information. Source attribution: BBC Business. Source: BBC Business - https://www.bbc.co.uk/news/articles/c3v0rzd2l17o?at_medium=RSS&at_campaign=rss
